December 2021
-
12.20.2021 Partnerships Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply -
12.17.2021 Partnerships Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine -
12.16.2021 Covid-19 Vaccines Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of COMIRNATY® in Adolescents 12 Through 15 Years of Age -
12.03.2021 Medicines FDA Issues Update to XELJANZ® Prescribing Information in the United States
November 2021
-
11.23.2021 Medicines Important Update on EpiPen® (epinephrine injection, USP) 0.3 mg Auto-Injectors
October 2021
-
10.11.2021 Covid-19 Medicines Vaccines Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union
September 2021
-
09.17.2021 Medicines Pfizer Expands Voluntary Nationwide Recall to include All Lots of CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline Content -
09.06.2021 Covid-19 Vaccines Pfizer and BioNTech Submit a Variation to EMA with the Data in Support of a Booster Dose of COMIRNATY® -
09.03.2021 Medicines The Bristol-Myers Squibb-Pfizer Alliance is pleased with the decision by the U.S. Court of Appeals for the Federal Circuit upholding the Eliquis®Patents -
09.01.2021 Covid-19 First Participant Dosed in Phase 2/3 Study of Oral Antiviral Candidate in Non-Hospitalized Adults with COVID-19 Who Are at Low Risk of Severe Illness -
09.01.2021 Covid-19 Research First Participant Dosed in Phase 2/3 Study of Oral Antiviral Candidate in Non-Hospitalized Adults with COVID-19 Who Are at Low Risk of Severe Illness -
09.01.2021 Medicines FDA Issues Drug Safety Communication Related to Current XELJANZ® Label